PsyBio Therapeutics Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSYB.V research report →
Companywww.psybiolife.com
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. The company is headquartered in Coconut Creek, Florida.
- CEO
- Evan Mike Levine
- IPO
- 2021
- Employees
- 4
- HQ
- Coconut Creek, FL, US
Price Chart
Valuation
- Market Cap
- $956.54K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -867.29%
- ROIC
- 328.61%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,886,000 · 55.66%
- EPS
- $-0.04 · 58.00%
- Op Income
- $-4,555,000
- FCF YoY
- 50.52%
Performance & Tape
- 52W High
- $0.14
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.03
- Beta
- 0.66
- Avg Volume
- 166.84K
Get TickerSpark's AI analysis on PSYB.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PSYB.V Coverage
We haven't published any research on PSYB.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PSYB.V Report →